Conmed vs Teleflex
CNMD and TFX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNMD and TFX compare
Teleflex is the larger company, worth 4.5 times as much as Conmed ($6.7B against $1.5B).
Teleflex grew revenue faster over the last twelve months (30.7% versus 1.6% for Conmed).
Conmed keeps more of each dollar of sales as profit, with a net margin of 5.4% compared with −45.8% at Teleflex.
Teleflex pays a dividend yielding 0.65%; Conmed does not pay one.
Conmed scores higher on the StockData Score (14 against 7 for Teleflex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNMD | TFX |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $6.7B |
| Share price | $49.35 | $157.10 |
| Change, 1 year | 14.1% | 43.5% |
| Change, 5 years | −63.5% | −48.5% |
| Beta (5Y) | 0.35 | 0.37 |
| Employees | 3,900 | 16K |
| StockData Score | ||
| Total score | 14 (better) | 7 |
| Valuation score | 6 (better) | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 20.4× | – |
| P/S | 1.1× (better) | 3.0× |
| P/B | 1.4× (better) | 2.3× |
| EV/EBITDA | 16.5× (better) | 47.6× |
| P/FCF | 11.1× (better) | 39.5× |
| FCF yield | 9.0% (better) | 2.5% |
| Fair value | $67.98 | $37.82 |
| Margin of safety | 27.4% (better) | −315% |
| Growth | ||
| Revenue growth (TTM) | 1.6% | 30.7% (better) |
| Revenue growth, 5Y average | 9.8% (better) | −4.7% |
| Net income growth (TTM) | 14.6% (better) | −638% |
| EPS growth (TTM) | 18.0% (better) | −645% |
| EPS growth, 5Y average | 36.4% | – |
| Profitability | ||
| Gross margin | 57.6% (better) | 54.9% |
| Operating margin | 9.9% (better) | 2.0% |
| Net margin | 5.4% (better) | −45.8% |
| FCF margin | 9.7% (better) | 7.5% |
| Return on equity | 7.1% (better) | −28.9% |
| Return on invested capital | 5.2% (better) | 0.62% |
| Financial health | ||
| Debt / equity | 0.77 (better) | 0.97 |
| Net debt / EBITDA | 5.66 (better) | 13.01 |
| Interest coverage | 4.1× (better) | 0.4× |
| Current ratio | 1.49 | 2.60 (better) |
| Altman Z-score | 2.01 (better) | 1.59 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | 0.65% (better) |
| Payout ratio | 8.4% | – |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | −5.6% | 0.00% (better) |
| Buyback yield | – | 3.8% |
| Shareholder yield | 0.00% | 4.4% (better) |
| Ownership | ||
| Held by institutions | 114% | 113% |
| Held by insiders | 0.47% | 0.73% |
| Insider net buying, 12 months | $0 | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 6.3% | 9.7% |
Go deeper
- CNMD stock overview
- CNMD income statement
- CNMD valuation and score
- TFX stock overview
- TFX income statement
- TFX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.